Epidemiology of cholangiocarcinoma

Abstract

Aim: We aimed to analyze temporal trends in mortality from intrahepatic (ICC) and extrahepatic (ECC) cholangiocarcinoma in selected countries worldwide.

Methods: Official death certification data for ICC and ECC and populations estimates for 29 countries worldwide (17 from Europe, 8 from the Americas, and 4 from Australasia) and for Hong Kong Special Administrative Region of the People’s Republic of China (SAR), from 1995 to 2018, were extracted from the World Health Organization and the Pan American Health Organization databases. Age-standardized mortality rates were computed. A joinpoint regression analysis was performed.

Results: In both sexes, ICC mortality rates increased in most countries considered, including the USA, the UK, and Australia; in some countries, including Italy and France, the increasing trends leveled off over the most recent years. In men, around 2016, the highest rates (1.7-2.3/100,000) were observed in Hong Kong SAR, Portugal, France, Spain, Australia, Austria, the UK, and Canada; Latin American countries and some eastern European countries had the lowest rates (0.2-0.8/100,000). A similar pattern was observed in women, but with lower rates (from 1.7/100,000 in Hong Kong SAR to 0.14/100,000 in Argentina). ECC mortality declined in most European and Australasian countries, but it tended to increase in Americas. In both sexes, rates were below 1/100,000 around 2016, with the only exceptions being Japan (2.6/100,000 men and 1.2/100,000 women) and Hungary (1.5/100,000 men and 1.1/100,000 women).

Conclusion: ICC mortality increased in most areas of the world, likely due to increased prevalence of risk factors and improved cancer recognition and classification. ECC mortality fell in most countries, largely due to the widespread use of cholecystectomy.

Keywords

Cholangiocarcinoma / mortality / epidemiology / temporal trends / intrahepatic cholangiocarcinoma / extrahepatic cholangiocarcinoma

References

[1] Banales JM,Carpino G.Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).Nat Rev Gastroenterol Hepatol2016;13:261-80

[2] Valle JW,Nervi B,Zhu AX.Biliary tract cancer.Lancet2021;397:428-44

[3] Mosconi S,Labianca R,Gatta G.Cholangiocarcinoma.Crit Rev Oncol Hematol2009;69:259-70

[4] Tyson GL.Risk factors for cholangiocarcinoma.Hepatology2011;54:173-84 PMCID:PMC3125451

[5] Razumilava N.Cholangiocarcinoma.Lancet2014;383:2168-79 PMCID:PMC4069226

[6] Wongjarupong N,Susantitaphong P.Non-alcoholic fatty liver disease as a risk factor for cholangiocarcinoma: a systematic review and meta-analysis.BMC Gastroenterol2017;17:149 PMCID:PMC5721586

[7] Choi J,Peeraphatdit T.Aspirin use and the risk of cholangiocarcinoma.Hepatology2016;64:785-96 PMCID:PMC5995727

[8] Banales JM,Lamarca A.Cholangiocarcinoma 2020: the next horizon in mechanisms and management.Nat Rev Gastroenterol Hepatol2020;17:557-88 PMCID:PMC7447603

[9] Shaib Y.The epidemiology of cholangiocarcinoma.Semin Liver Dis2004;24:115-25

[10] Ellington TD,Wilson RJ.Incidence and mortality of cancers of the biliary tract, gallbladder, and liver by sex, age, race/ethnicity, and stage at diagnosis: united states, 2013 to 2017.Cancer Epidemiol Biomarkers Prev2021;30:1607-14

[11] Gad MM,Faisaluddin M.Epidemiology of cholangiocarcinoma; united states incidence and mortality trends.Clin Res Hepatol Gastroenterol2020;44:885-93

[12] Rizvi S,Hallemeier CL,Gores GJ.Cholangiocarcinoma - evolving concepts and therapeutic strategies.Nat Rev Clin Oncol2018;15:95-111 PMCID:PMC5819599

[13] Welzel TM,Hsing AW,Pfeiffer RM.Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States.J Natl Cancer Inst2006;98:873-5

[14] Florio AA,Znaor A.Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012.Cancer2020;126:2666-78 PMCID:PMC7323858

[15] Saha SK,Fuchs CS.Forty-year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise.Oncologist2016;21:594-9 PMCID:PMC4861366

[16] Kim D,Cholankeril G,Ahmed A.Trends in the mortality of biliary tract cancers based on their anatomical site in the United States from 2009 to 2018.Am J Gastroenterol2021;116:1053-62

[17] Van Dyke AL,Jones GS.Biliary tract cancer incidence and trends in the United States by demographic group, 1999-2013.Cancer2019;125:1489-98 PMCID:PMC6467796

[18] Patel N.Incidence of cholangiocarcinoma in the USA from 2001 to 2015: a us cancer statistics analysis of 50 states.Cureus2019;11:e3962 PMCID:PMC6436669

[19] Bertuccio P,Carioli G.Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma.J Hepatol2019;71:104-14

[20] World Health Organization. WHO mortality database. Available from: https://www.who.int/data/data-collection-tools/who-mortality-database [Last accessed on 2 Apr 2022]

[21] World Health Organization. WHO mortality database. Available from: https://www.who.int/data/data-collection-tools/who-mortality-database [Last accessed on 7 Apr 2022]

[22] Pan American Health Organization (PAHO). Core indicators dashboard. Available from: https://opendata.paho.org/en/core-indicators/core-indicators-dashboard [Last accessed on 7 Apr 2022]

[23] Smith PG.Cancer Incidence in Five Continents. Comparison between registries: age-standardized rates.IARC Sci Publ1992:856-70.

[24] National Cancer Institute. Joinpoint trend analysis software. Available from: https://surveillance.cancer.gov/joinpoint/ [Last accessed on 2 Apr 2022]

[25] Kim HJ,Feuer EJ.Permutation tests for joinpoint regression with applications to cancer rates.Stat Med2000;19:335-51

[26] Welzel TM,El-Serag HB.Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study.Clin Gastroenterol Hepatol2007;5:1221-8 PMCID:PMC2083573

[27] Petrick JL,Altekruse SF.Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based study in SEER-Medicare.PLoS One2017;12:e0186643 PMCID:PMC5648218

[28] Shaib YH,Nooka AK.Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case-control study.Am J Gastroenterol2007;102:1016-21

[29] Palmer WC.Are common factors involved in the pathogenesis of primary liver cancers?.J Hepatol2012;57:69-76 PMCID:PMC3804834

[30] De Lorenzo S,Mazzotta A.Non-alcoholic steatohepatitis as a risk factor for intrahepatic cholangiocarcinoma and its prognostic role.Cancers (Basel)2020;12:3182 PMCID:PMC7692633

[31] Jing W,Zhou X.Diabetes mellitus and increased risk of cholangiocarcinoma: a meta-analysis.Eur J Cancer Prev2012;21:24-31

[32] Petrick JL,Zeleniuch-Jacquotte A.Body mass index, diabetes and intrahepatic cholangiocarcinoma risk: the liver cancer pooling project and meta-analysis.Am J Gastroenterol2018;113:1494-505 PMCID:PMC6521884

[33] Corrao S,Argano C.Nonalcoholic fatty liver disease is associated with intrahepatic cholangiocarcinoma and not with extrahepatic form: definitive evidence from meta-analysis and trial sequential analysis.Eur J Gastroenterol Hepatol2021;33:62-8

[34] El-Serag HB,Landgren O.Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: a population-based study of U.S. veterans.Hepatology2009;49:116-23 PMCID:PMC2719902

[35] Clements O,Kim JU,Khan SA.Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a systematic review and meta-analysis.J Hepatol2020;72:95-103

[36] Hales CM,Carroll MD,Ogden CL.Trends in obesity and severe obesity prevalence in US youth and adults by sex and age, 2007-2008 to 2015-2016.JAMA2018;319:1723-5 PMCID:PMC5876828

[37] Estes C,Loomba R,Sanyal AJ.Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease.Hepatology2018;67:123-33 PMCID:PMC5767767

[38] Hofmeister MG,Barker LK.Estimating prevalence of hepatitis C virus infection in the United States, 2013-2016.Hepatology2019;69:1020-31 PMCID:PMC6719781

[39] Centers for Disease Control and Prevention. Viral hepatitis surveillance, 2019. Available from: https://www.cdc.gov/hepatitis/statistics/2019surveillance/index.htm [Last accessed on 2 Apr 2022]

[40] La Vecchia C,Bertuccio P.Trends in alcohol consumption in Europe and their impact on major alcohol-related cancers.Eur J Cancer Prev2014;23:319-22

[41] Ferrone CR,Shahid M.The Ability to diagnose intrahepatic cholangiocarcinoma definitively using novel branched DNA-enhanced albumin RNA in situ hybridization technology.Ann Surg Oncol2016;23:290-6 PMCID:PMC4472634

[42] Tyson GL,Duan Z.Secular trends in the incidence of cholangiocarcinoma in the USA and the impact of misclassification.Dig Dis Sci2014;59:3103-10 PMCID:PMC4823008

[43] Bertuccio P,Carioli G.Global trends and predictions in hepatocellular carcinoma mortality.J Hepatol2017;67:302-9

[44] Chow WH,Gridley G.Gallstones, cholecystectomy and risk of cancers of the liver, biliary tract and pancreas.Br J Cancer1999;79:640-4 PMCID:PMC2362428

[45] Levi F,Negri E.The recent decline in gallbladder cancer mortality in Europe.Eur J Cancer Prev2003;12:265-7

[46] Bertuccio P,Carioli G.Reply to: “How to predict global trends in HCC mortality if neglect more than half the world’s cases?.J Hepatol2017;67:888